openPR Logo
Press release

FDA Grants Compassionate Use of Alzheimer's Drug TB006, Now Accessible in Southern Florida

05-06-2025 12:10 AM CET | Health & Medicine

Press release from: Getnews

/ PR Agency: Brand Featured
FDA Grants Compassionate Use of Alzheimer's Drug TB006, Now

West Palm Beach, FL - May 5, 2025 - Brain Power Clinics, a Florida-based healthcare provider specializing in cognitive conditions, announces the availability of TB006 for compassionate use in the treatment of Alzheimer's disease. The new drug, currently in clinical trials, has shown promising early results in addressing memory loss and other symptoms associated with dementia.

Promising New Treatment for Alzheimer's Disease

TB006, now available through Brain Power Clinics in Southern Florida, is designed to reduce inflammation in the brain by targeting galectin3, a protein linked to Alzheimer's pathology. This mechanism may help dissolve the amyloid plaques and tau tangles that contribute to cognitive decline.

According to Dr. Arbella Sarkis, the chief investigator in the ongoing clinical trial, more than 400 patients have received TB006 with no reported side effects. "Approximately 70-80% of participants have experienced improvement in cognitive functions," Dr. Sarkis stated.

Expert and Community Endorsements

Dr. Josh Helman, a Harvard-trained physician, has presented findings related to TB006 at A4M, a conference focused on anti-aging medical advancements. His presentation received strong interest due to the drug's potential in helping individuals with early-stage dementia and memory impairment. Dr. Helman is the Chief Medical Officer of Brain Power Clinics. He has been treating patients with TB006 over the past year, and has seen excellent results in his patients.

Philanthropic support has also grown. Robert Buechner, Chairman of The BeEx Foundation and a long-time advocate for Alzheimer's research, has backed the initiative. "For the first time in decades, we are seeing encouraging results that deserve wider attention," Buechner said.

Access Remains Limited but Growing

Despite the positive data, TB006 is still in a controlled trial phase, limiting the number of healthcare providers who can offer it. Brain Power Clinics is currently one of the few centers in the U.S. administering the treatment.

Preliminary results shared by the drug's manufacturer show that patients receiving TB006 demonstrated improved cognitive performance and reduced brain inflammation after three months of use compared to a placebo group. However, broader trials are needed to validate long-term outcomes.

Patients and families dealing with memory challenges or early signs of Alzheimer's are encouraged to learn more about eligibility and access.

Text "Memory" to 728-203-3131 or visit www.BrainPowerClinics.com [http://www.brainpowerclinics.com/] for more information.

About Brain Power Clinics

Brain Power Clinics, based in Palm Beach County, Florida, focuses on diagnosing and supporting individuals with dementia, cognitive decline, and memory-related issues. The clinic is dedicated to providing access to cutting-edge treatments under FDA oversight and compassionate use protocols.
Media Contact
Company Name: Brain Power Clinics
Contact Person: Dr. Robert Love
Email: Send Email [http://www.universalpressrelease.com/?pr=fda-grants-compassionate-use-of-alzheimers-drug-tb006-now-accessible-in-southern-florida]
Phone: 728-203-3131
Country: United States
Website: http://www.brainpowerclinics.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release FDA Grants Compassionate Use of Alzheimer's Drug TB006, Now Accessible in Southern Florida here

News-ID: 4000167 • Views:

More Releases from Getnews

Inspire Ambitions Unveils New Report Showing Graduate Expectation Gap in the UAE Workforce
Inspire Ambitions Unveils New Report Showing Graduate Expectation Gap in the UAE …
Inspire Ambitions launches "The 2025 Graduate Expectation Gap Report," highlighting disconnects between student career expectations and workplace realities. Image: https://www.globalnewslines.com/uploads/2025/09/6f6df43eab6fb7f22996fcc669a39629.jpg A new report released today by Inspire Ambitions [https://inspireambitions.com/], The 2025 Graduate Expectation Gap Report [https://inspireambitions.com/product/from-campus-to-career/], reveals that a significant majority of recent graduates in the UAE feel unprepared for the realities of today's workplace. The findings shed light on a widening divide between university preparation and the skills needed to succeed
Future Electronics and Infineon to Host Free Webinar on Next-Generation Smart HMI Design with PSOC Trademark Edge
Future Electronics and Infineon to Host Free Webinar on Next-Generation Smart HM …
Image: https://www.globalnewslines.com/uploads/2025/09/1757697276.jpg Future Electronics & Infineon's free webinar on Sept 25 to explore how PSOC Trademark Edge powers next-gen smart HMIs with AI, voice & gesture control. Montreal, Canada - September 12, 2025 - Future Electronics, a leading global distributor of electronic components, is pleased to announce an upcoming free webinar hosted in collaboration with Infineon Technologies: Unlock Innovation with PSOC Trademark Edge for Next-Gen Smart HMIs. The live session will take place
RoadMap Advisors Enhances Sell-Side M&A Services for Middle Market Business Owners
RoadMap Advisors Enhances Sell-Side M&A Services for Middle Market Business Owne …
Image: https://www.globalnewslines.com/uploads/2025/09/1757662626.jpg RoadMap Advisors, a Virginia-based consulting firm, has refined its sell-side M&A service offerings to provide greater process efficiency, buyer alignment, and transaction readiness for business owners seeking full or partial exits. Vienna, VA - September 12, 2025 - RoadMap Advisors, a leading consulting firm in Tysons, VA [https://www.roadmapadvisors.com/], has announced the refinement of its sell-side mergers and acquisitions (M&A) services [https://www.roadmapadvisors.com/mergers-acquisitions/sell-side/], incorporating a structured, advisor-led process designed to help business
MFE Insurance Responds to Industry Shift as Studios Turn to DICE Insurance for Innovative Productions
MFE Insurance Responds to Industry Shift as Studios Turn to DICE Insurance for I …
Image: https://www.globalnewslines.com/uploads/2025/09/1757659532.jpg MFE Insurance is offering custom DICE insurance policies for studios and filmmakers seeking to innovate their productions. Los Angeles, CA - September 12, 2025 - As audience expectations continue to shift and demand for high-impact, visually memorable content rises, producers and production companies are pushing creative boundaries like never before. MFE Insurance, a national leader in entertainment, cannabis, and event insurance, [https://www.mfeinsurance.com/] is meeting that evolution head-on with customized DICE

All 5 Releases


More Releases for TB006

Alzheimer's Disease Clinical Trials 2025: EMA, PDMA, FDA Approvals, Treatment Ma …
(Albany, USA) DelveInsight's 'Alzheimer's disease Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Alzheimer's disease therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Alzheimer's disease pipeline domain. For Alzheimer's disease emerging drugs, the Alzheimer's disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration,
04-21-2025 | Health & Medicine
Getnews
New Investigational Drug TB006 FDA - Approved For Compassionate Use
Naples, FL - April 21, 2025 - TB006, a new investigational drug, has been approved by the US Food and Drug Administration (FDA) for compassionate use and is currently being evaluated in a clinical trial for Alzheimer's disease. The FDA's compassionate use designation allows patients with serious or life-threatening conditions to access investigational treatments when no satisfactory alternatives are available. TB006 is currently undergoing clinical trials to assess its safety and
Alzheimer's Disease Drug Development Pipeline: 2025-A Surge in Innovation as 110 …
DelveInsight unveils its latest report, highlighting the evolving landscape of the Alzheimer's disease pipeline, with over 110 pharma and biotech companies like BioVie, Novo Nordisk, Alector, Longeveron, Cognition Therapeutics, TrueBinding, VT BIO, Luye Pharma Group, Lexeo Therapeutics, Merck Sharp & Dohme LLC, and Regeneration Biomedical, advancing novel Alzheimer's disease drugs set to reshape the Alzheimer's disease market. The fight against Alzheimer's disease is gaining momentum. In its newly released "Alzheimer's disease
Dementia Market 2032: Epidemiology Data, Pipeline Breakthroughs, Regulatory Land …
The Dementia Market size was valued approximately USD 21 million in 2021 and the report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the 7MM. DelveInsight's "Dementia Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the United States, EU4 (Germany, Spain, Italy,
Ischemic Stroke Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Ischemic Stroke Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Ischemic Stroke Pipeline Report • Over 50+ Ischemic Stroke
Alzheimer's Disease Drug Pipeline Analysis: FDA Approvals, Clinical Trials, Ther …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Alzheimer's disease pipeline constitutes 150+ key companies continuously working towards developing 160+ Alzheimer's disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Alzheimer's disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alzheimer's disease Market. The Alzheimer's disease Pipeline report